Awaiting development: Guidance and quality standards

Showing 241 to 250 of 335

Guidance and quality standards awaiting development
Title	Type
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356	Technology appraisal guidance
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905	Technology appraisal guidance
Resminostat for maintenance treatment of advanced mycosis fungoides or Sézary syndrome ID6478	Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436	Technology appraisal guidance
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]	Technology appraisal guidance
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]	Technology appraisal guidance
Rivaroxaban for treating chronic heart failure [ID1462]	Technology appraisal guidance
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]	Technology appraisal guidance
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764	Technology appraisal guidance
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763	Technology appraisal guidance